QQ客服 官方微博 反馈留言

浏览/检索结果: 共7条，第1-7条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序提交时间升序提交时间降序题名升序题名降序作者升序作者降序 Furmonertinib (Alflutinib, AST2818) is a potential positive control drug comparable to rifampin for evaluation of CYP3A4 induction in sandwich-cultured primary human hepatocytes 期刊论文 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10 作者:  Wu, Ya-li;  Xue, Ya-ru;  Guo, Zi-tao;  Chen, Zhen-dong;  Ge, Xin-yu 收藏  |  浏览/下载：20/0  |  提交时间：2021/08/17 furmonertinib (alflutinib  AST2818)  quantitative proteomics  sandwich-cultured human hepatocytes   Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers 期刊论文 INVESTIGATIONAL NEW DRUGS, 2021, 页码: 8 作者:  Zhu, Yun-ting;  Zhang, Yi-fan;  Jiang, Jin-fang;  Yang, Yong;  Guo, Li-xia 收藏  |  浏览/下载：26/0  |  提交时间：2021/05/24 Alflutinib  Rifampicin  CYP3A4  AST5902  Drug-drug interaction   Characterization of covalent binding of tyrosine kinase inhibitors to plasma proteins 期刊论文 DRUG METABOLISM AND PHARMACOKINETICS, 2020, 卷号: 35, 期号: 5, 页码: 456-465 作者:  Liu, Xiaoyun;  Feng, Dan;  Zheng, Mingyue;  Cui, Yongmei;  Zhong, Dafang 收藏  |  浏览/下载：13/0  |  提交时间：2020/12/21 Covalent tyrosine kinase inhibitors  Covalent binding  Human serum albumin  Molecular docking  Quantitative calculations  Linear modeling  Species difference   Safety, Clinical Activity, and Pharmacokinetics of Al flutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation 期刊论文 JOURNAL OF THORACIC ONCOLOGY, 2020, 卷号: 15, 期号: 6, 页码: 1015-1026 作者:  Shi, Yuankai;  Zhang, Shucai;  Hu, Xingsheng;  Feng, Jifeng;  Ma, Zhiyong 收藏  |  浏览/下载：36/0  |  提交时间：2020/12/24 Alflutinib  NSCLC  EGFR T790M mutation  Efficacy  Safety   Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer 期刊论文 ACTA PHARMACOLOGICA SINICA, 2020, 页码: 11 作者:  Liu, Xiao-yun;  Guo, Zi-tao;  Chen, Zhen-dong;  Zhang, Yi-fan;  Zhou, Jia-lan 收藏  |  浏览/下载：76/0  |  提交时间：2020/07/01 alflutinib  AST5902  metabolism  enzyme induction  drug-drug interaction   Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry 期刊论文 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2019, 卷号: 176, 页码: 6 作者:  Liu, Xiaoyun;  Li, Wei;  Zhang, Yifan;  Jian, Yong;  Zhao, Qianyu 收藏  |  浏览/下载：14/0  |  提交时间：2020/07/01 LC-MS/MS  Alflutinib  AST2818  Pharmacokinetics  Human plasma   Third Generation EGFR Inhibitor AST2818 (Alflutinib) in NSCLC Patients with EGFR T790M Mutation: A phase1/2 Multi-Center Clinical Trial 期刊论文 2017, 卷号: 12, 期号: 11, 页码: S2137-S2137 作者:  Shi, Y.;  Hu, X.;  Zhang, S.;  Yang, N.;  Zhang, Y. 收藏  |  浏览/下载：15/0  |  提交时间：2020/01/04 Targeted therapy  Third generation EGFR TKI  EGFR T790M mutant NSCLC